REGN vs. SNY: Regeneron Pharmaceuticals vs. Sanofi Stock Comparison

Company Profile

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Regeneron Pharmaceuticals (REGN) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for REGN.

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

Both Regeneron Pharmaceuticals (REGN) at 40.46% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Regeneron Pharmaceuticals (REGN) at 8.19% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Both Regeneron Pharmaceuticals (REGN) at 0.08 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Regeneron Pharmaceuticals (REGN) reports 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Regeneron Pharmaceuticals (REGN) at 19.99 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Regeneron Pharmaceuticals (REGN) at 2.71 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics